| Literature DB >> 33039614 |
Kevin Zhang1, Thomas N Vilches2, Mehreen Tariq3, Alison P Galvani4, Seyed M Moghadas3.
Abstract
OBJECTIVES: A hasty reopening has led to a resurgence of the novel coronavirus disease 2019 (COVID-19) in the United States (US). We aimed to quantify the impact of several public health measures including non-medical mask-wearing, shelter-in-place, and detection of silent infections to help inform COVID-19 mitigation strategies.Entities:
Keywords: COVID-19; Isolation; Mask-wearing; Shelter-in-place
Mesh:
Year: 2020 PMID: 33039614 PMCID: PMC7544634 DOI: 10.1016/j.ijid.2020.10.002
Source DB: PubMed Journal: Int J Infect Dis ISSN: 1201-9712 Impact factor: 3.623
Model parameters, values, and distributions.
| Description | 0–4 | 5–19 | 20–49 | 50–64 | ≥ 65 | Source | |
|---|---|---|---|---|---|---|---|
| Transmission probability per contact during the pre-symptomatic stage | 0.08 | Calibrated to | |||||
| Incubation period (days) | Log-Normal (mean: 5.2, SD: 0.1) | ( | |||||
| Asymptomatic period (days) | Gamma (shape: 5, scale: 1) | Derived from | |||||
| Pre-symptomatic period (days) | Gamma (shape: 1.058, scale: 2.174) | ( | |||||
| Infectious period from onset of symptoms (days) | Gamma (shape: 2.768, scale: 1.1563) | Derived from | |||||
| Proportion of infections that are asymptomatic | 0.3 | 0.31 | 0.29 | 0.29 | 0.18 | ( | |
| Proportion of symptomatic cases that exhibit mild symptoms | 0.95 | 0.9 | 0.85 | 0.60 | 0.20 | ( | |
| Relative transmissibility of severe symptomatic compared to pre-symptomatic | 0.89 | ( | |||||
| Relative transmissibility of mild symptomatic compared to pre-symptomatic | 0.44 | ( | |||||
| Relative transmissibility of asymptomatic compared to pre-symptomatic | 0.11 | ( | |||||
| Proportion of individuals with one or more comorbidities | 0.05 | 0.1 | 0.28 | 0.55 | 0.76 | ( | |
| Proportion of cases hospitalized with one or more comorbidities | 40% | ( | |||||
| Proportion of cases hospitalized with one or more comorbidities – by type of bed occupied | Non-ICU | 67% | |||||
| ICU | 33% | ||||||
| Proportion of cases hospitalized without any comorbidities | 9% | ( | |||||
| Proportion of cases hospitalized without any comorbidities – by type of bed occupied | Non-ICU | 75% | |||||
| ICU | 25% | ||||||
| Length of non-ICU stay | Gamma (shape: 4.5, scale: 2.75) | Derived from | |||||
| Length of ICU stay | Gamma (shape: 4.5, scale: 2.75) | Derived from | |||||
| Efficacy of mask in preventing transmission (eM) | 20% | ( | |||||
Shelter-in-place strategies implemented in the model.
| Scenario | Who is sheltered-in-place? | % of the population |
|---|---|---|
| S1 | Children aged 5 to 19 (school closures) | 18.9 |
| S2 | All individuals with comorbidities associated with COVID-19 | 36.3 |
| S3 | All individuals between 50 and 64 years of age | 18.9 |
| S4 | All individuals aged 65 and older | 16.6 |
| S5 | All individuals aged 50 and older | 35.6 |
| S6 | All individuals with comorbidities associated with COVID-19 or aged 50 to 64 | 44.9 |
| S7 | All individuals with comorbidities associated with COVID-19 or 65 and older | 40.3 |
| S8 | All individuals with comorbidities associated with COVID-19 or 50 and older | 48.9 |
Figure 1(A) Projected incidence of COVID-19 infections per 10,000 population at different mask-wearing compliance rates and with 5% level of pre-existing immunity. (B) Reductions in attack rate, hospitalizations, and deaths at different mask-wearing compliance rates compared to no mask-wearing. Simulations correspond to mask-wearing scenarios in the absence of shelter-in-place strategies.
Figure 2Projected incidence of COVID-19 with different shelter-in-place strategies combined with mask-wearing compliance rates of 0% (A), 25% (B), 50% (C), and 75% (D) among those not sheltered-in-place. The level of pre-existing immunity in the population was assumed to be 5% for all scenarios.
Figure 3Reductions achieved in attack rate, hospitalizations, and deaths with each shelter-in-place strategy combined with mask-wearing compliance rates of 0% (A1, B1, C1), 25% (A2, B2, C2), 50% (A3, B3, C3), and 75% (A4, B4, C4). The level of pre-existing immunity in the population was assumed to be 5% for all scenarios.
Figure 4Efficiency of various shelter-in-place strategies as the ratio of the number of adverse outcomes (infections, hospitalizations, and deaths) averted relative to the number of individuals sheltered-in-place in the absence of mask-wearing.
Figure 5Projected attack rates under different shelter-in-place strategies with a detection rate of 33% for silent (i.e., pre-symptomatic and asymptomatic) infections and mask-wearing compliance rates of 0% (A), 25% (B), 50% (C), and 75% (D).